(Form to be on hospital headed paper)

THIS STUDY HAS BEEN REVIEWED AND APPROVED BY A RECOGNISED RESEARCH ETHICS COMMITTEE

INFORMATION SHEET FOR PATIENTS/ VOLUNTEERS IN CLINICAL RESEARCH PROJECT

Title of Project: PARP Inhibitor Resistance Study (PAIRS) COHORT A

IRAS ID: 297051

Introduction

We would like to invite you to take part in our research study. Before you decide, it is important for you to understand why the research is being done and what it will involve. Please take time to read the following information carefully and discuss it with friends, relatives, and your GP if you wish. Ask us if there is anything that is not clear or if you would like more information. Take time to decide whether you wish to take part.

Why have I been invited to take part?

You have been invited to take part in this study because you have received treatment for ovarian cancer and you are about to start, have recently started, or have completed treatment with a drug known as a PARP inhibitor.

Do I have to take part?

No, taking part in the study is entirely voluntary. It is up to you to decide whether or not to take part. If you *do* decide to take part, you will be given this information sheet to keep and asked to sign a consent form. You are still free to withdraw at any time without giving a reason. This will not affect the quality of care you receive.

Taking part in this study will have no effect on the treatment decisions you make with your consultant.

If you decide *not* to take part in the study, it will not affect the quality of your treatment in any way.

Part 1 – What's Involved: Tells you the purpose of this trial and what will happen to you if you take part.

Part 2 – Supporting / Further Information: Gives you more detailed information about the study.

PART 1 – WHAT'S INVOLVED

What is the purpose of the study?

The purpose of the PAIRS study is to collect tumour samples from women with ovarian cancer who are treated with PARP inhibitors and then analyse them to understand why some women benefit from PARP inhibitor therapy while others do not. We would then be able to use PARP inhibitors in a more personalised way. Patients who are unlikely to respond to PARP inhibitors would not receive them, but those who are likely to benefit will do.

What does the study involve?

This is a sample collection study. We will ask you if we can access the tumour sample taken before you started PARP inhibitor treatment (e.g. samples taken at diagnosis or during previous surgery). We will take extra blood samples at the time of your routine blood tests. Another tumour biopsy will be taken if your cancer gets worse during/after treatment with a PARP inhibitor. The tumour samples will be tested in the laboratory to learn more about markers that might predict response or resistance to PARP inhibitor therapy. Clinical information about your cancer and cancer treatments will be recorded.

We want to recruit 260 patients over 3 years. If you decide to take part in the study, you would be asked to stay in the study until six months after your cancer gets worse or until the study ends. You can choose to come off the study at any time without needing to give a reason.

What will happen to me if I take part?

If you decide to take part in this study, you will be asked to sign a consent form and will be given a copy to keep, along with a copy of this patient information sheet. Your study doctor/nurse will then check your medical records to decide

if you can take part. Clinical information about your cancer history will be recorded and any previous samples of tissue from your cancer will be studied.

If you agree to take part, you will continue to have appointments with your doctor/nurse and regular blood samples will be taken. Every 3-4 months, an extra blood sample will be taken for the study and clinical information about your cancer will be recorded. At one visit, we will also take a blood sample for storage. This is because we may identify mutations in genes that you inherited from your parents that might have caused your cancer to develop. If this happens, we would want to send the sample in storage for a confirmatory test.

If your cancer does not get worse during the study, we want you to be part of the study until it ends.

If your cancer gets worse during/after treatment with a PARP inhibitor, you will be asked to have another tumour biopsy (using a needle) and a blood sample taken. Exactly where the biopsy sample will be taken from depends on where your tumour has progressed. The biopsy may be done using ultrasound or CT scanning to guide the doctor. Some patients whose cancer has got worse on a PARP inhibitor may have an operation to remove the tumour. Your doctor will discuss with you whether this is right for you. If you are going to have surgery, you would not need a separate biopsy for the study since we would ask tissue to be taken for the study during your operation instead. Clinical information about your cancer will be recorded for the study. Your doctor will discuss with you what your treatment options are once your cancer has progressed on a PARP inhibitor. The study will not have any influence on these options.

At consultation, around 6 months after the additional tumour biopsy was taken, your study doctor/nurse will collect further information about your cancer and cancer treatments. This can be done at an online virtual appointment or by coming to the clinic.

What elements of the study are additional to standard care?

The biopsy and additional blood samples taken in the study are not needed for your usual treatment. The blood samples for the study will be taken at the same time as blood samples required for standard care.

What elements of standard care may I not receive if I agree to take part in

this study?

Participation in this study will not affect your normal treatment. Your doctor/nurse will give you PARP inhibitor treatment for as long as they think it is helping you.

Clinic attendance

During your PARP inhibitor treatment, you will need to see your doctor/nurse and have blood tests regularly. Usually this is every month at the beginning and then may be less often once your PARP inhibitor dose is right. Many cancer centres are doing some of these visits over the phone or video (virtually) with blood samples taken at your GP surgery or a local blood sampling service. But the blood samples for the study will need to be taken at your cancer centre. So every 3 or 4 months the usual blood samples will be taken at your cancer centre, and the study blood samples will be taken at the same time. This may mean that your hospital visit takes around 30 minutes longer.

If you need to have a biopsy sample taken the visit may take several hours. Depending on where the biopsy is taken from, you may need to be observed after the biopsy for around 4 hours. As this visit is additional to standard treatment, we will pay your travel expenses.

The follow up visit 6 months after the biopsy can happen virtually or at a clinic attendance.

What are the possible disadvantages and risks of taking part?

If at any time in the study you need to have a biopsy sample taken this may cause side effects. There may be bruising, pain and/or infection at the biopsy site. A local anaesthetic may be given before the biopsy and pain killers prescribed afterwards. If you get an infection you may need antibiotics. Infection is unusual and only about one in a hundred people get this problem. Very rarely the biopsy causes bleeding severe enough that a blood transfusion or even another minor operation is needed. The risk of other side effects of the biopsy will depend on where the biopsy is taken from. For example, if it is a lung biopsy there would be a small chance of having a pneumothorax (air leaking around the outside of the lung which can sometimes cause shortness of breath). If the biopsy is done during a CT scan there is a very small chance of having an allergic reaction to the contrast material injected beforehand and very rarely this can cause kidney

damage. This CT scan would be extra to those you would normally have as part of your treatment. The radiation used can cause cell damage that may, after many years, turn cancerous. The chance of this happening to you is extremely small.

What are the possible benefits of taking part?

There will be no direct medical benefits to you from taking part in this study. But women diagnosed with ovarian cancer in the future will benefit from doctors knowing more about the sensitivity and resistance to PARP inhibitors. This means we may be able to spot the women who are unlikely to benefit from PARP inhibitor therapy, so they do not get that treatment and its side effects. We may also be able to find better alternative treatments for them and for women whose tumours develop resistance to PARP inhibitors.

PART 2 – SUPPORTING / FURTHER INFORMATION

What if something goes wrong?

If you are worried about any aspect of this study, you can speak to the study doctor or nurse at any time and they will do their best to answer your questions.

If something does go wrong, you are harmed during the research and this is due to someone's negligence, then you may have grounds for a legal action for compensation. But you may have to pay your legal costs. Even so, if you want to complain or have any concerns about any aspect of the way you have been approached or treated during the course of this study, the normal National Health Service complaints mechanism will still be available to you. If you do have a complaint, then please contact *(Insert local complaint department details here including contact name, number and address prior to printing patient information sheet on local headed paper)*.

Will my taking part in the study be kept confidential?

NHS Greater Glasgow and Clyde (NHS GG&C) is the Sponsor for this study based in the United Kingdom. NHS GG&C will be using information from you and your medical records for this study. The sponsor has agreed that the University of Glasgow will act as the data controller for this study. This means that University of Glasgow is responsible for looking after your information and using it

properly. NHS GG&C will keep identifiable information about you for 5 years after the study has finished.

Your rights to access, change or move your information are limited, as we need to manage your information in specific ways for the research to be reliable and accurate. If you withdraw from the study, we will keep the information about you that we have already have. To safeguard your rights, we will use the least amount of information possible that could identify you personally.

You can find out more about how we use your information at
https://www.hra.nhs.uk/information-about-patients/

You can be assured that any data collected during this study and any of the results published will not identify you personally. Your medical records will only be available to the study doctors, your hospital consultant, responsible individuals from the Cancer Research UK Glasgow Clinical Trials Unit (CTU) and the study Sponsor. Information about you may also be looked at by staff from Wellbeing of Women and/or Artios Pharma Limited as they are funding this study. The purpose of this would be to check that the study is being carried out correctly but they would not be able to identify you.

We will tell your general practitioner (GP) that you are taking part in this study. The GP will be told details of your diagnosis, a summary of the study, the expected risks of collecting blood samples and taking a tumour biopsy, and any update on your progress. Contact details will be given to your GP if he/she has any questions or concerns about the study or if he/she has any concerns if you were to become unwell.

The CRUK Glasgow CTU, which is co-ordinating the study, will collect your initials, year of birth and sex at birth at the time you are registered on to the study. This information will be stored securely and will be kept strictly confidential, with access provided only to authorised personnel who are performing analysis for the study.

Your consent for taking part in this study includes your consent for the information in your clinical record to be used for future cancer research. You can also consent to allow these data to be linked to data coming from other sources such as cancer registries and medical clinical records. All data (personal, clinical, economic, and data coming from research on biological material)

collected on your behalf will be treated in compliance with the relevant European and UK laws to ensure your confidentiality is maintained.

What will happen to any samples I give?

You will also be asked to consent to provide extra blood samples that will be used specifically for research purposes. These would be up to 50 millilitres (ten teaspoonfuls) and would be taken at your clinic visits.

You will also be asked to consent for the research team to collect samples of the tumour tissue that was taken originally to diagnose your cancer or removed at the time of an operation and was not needed for your routine diagnosis.

You will also be asked to consent for the research team to collect a tumour biopsy sample if your cancer gets worse during treatment with a PARP inhibitor. If you have surgery to remove a tumour that is increasing in size, the sample for the study can be taken from the surgical specimen and no extra biopsy is required.

All samples (blood and tumour) will be sent to a laboratory in the UK (Western General Hospital, Edinburgh) initially but could be sent to laboratories around the world for further analysis. These samples will not contain any information that would identify you. With your permission, they may be used for other ethically approved and relevant investigations that would be conducted by qualified researchers in academic or commercial organisations (in the UK or worldwide).

The analysis of the samples will involve looking at the genetic make-up (DNA) of your tumour and blood samples. It is possible that we could find a DNA abnormality that has implications for the cancer risk of your relatives (known as a germ-line genetic aberration). In most cancer centres it is standard for women with ovarian cancer to give a blood sample which is tested for abnormalities in a panel of genes. Therefore many of women (around 10 to 20%) will already know that they have a germ-line genetic aberration and have been referred to clinical genetic services who help assess the cancer risk of relatives and the need for wider genetic testing. If we do find that you have a genetic aberration that is not already known about, we will store some DNA. The abnormality can then be confirmed in another clinical laboratory and we will refer you to a clinical genetics service so that you and your family can get the information to

understand better what the finding means.

You can choose not to be told about any aberrations that you have inherited. This would also mean that we would not tell any member of your family.

It is unlikely that we will complete the tests on your blood and tumour samples until some time after they have been taken. It may take up to 4 years for all the tests to be performed on all the samples.

What will happen to the results of the study?

When the study ends, the data will be analysed and the results presented at national and international scientific and medical conferences before being published in a medical journal. The results will also be published on the Cancer Research UK website. The confidentiality of all patients will be maintained. You will not be personally identified in any reports or publications resulting from the study. If you would like to have a copy of the published results, please check the Cancer Research UK website or ask your study doctor.

Who is organising and funding this research?

The study is being sponsored by NHS Greater Glasgow and Clyde, and is being co-ordinated by the Cancer Research UK Clinical Trials Unit (Glasgow), which is based at the Beatson West of Scotland Cancer Centre in Glasgow. Financial support will be provided by Wellbeing of Women and Artios Pharma Limited.

None of the doctors or other staff conducting the research are being paid directly for recruiting patients into the study.

How have patients and public been involved in this study?

We have engaged with volunteers from the Ovarian Cancer Action Research Network. They are involved in reviewing the study from development and will be involved throughout as the study progresses as part of the Trial Management Group.

Who has reviewed this study?

This study has been reviewed by a number of medical specialists during its development including the NCRI Ovarian Cancer Subgroup Committee and Wellbeing of Women. The study has also been reviewed and approved by the

Sponsor's Research and Innovation Department and the Health Research Authority (HRA) Research Ethics Service [West of Scotland Research Ethics Committee (5)] to confirm that the study respects patients' rights and the protection of patients' health.

Contact for further information

If you have further questions about your illness or about clinical studies, please discuss them with your study doctor.

If you would like independent advice of further information you may also find it useful to contact:

Macmillan Cancer Support, an independent patient advisory group (freephone 0808 808 0000); website http://www.macmillan.org.uk, Head Office Address: Macmillan Cancer Support, 89 Albert Embankment, London, SE1 7UQ

Cancerhelp UK (Cancer Research UK), who provide a wide range of information for people with cancer: Freephone: 0808 800 4040, and website: www.cancerhelp.org.uk.

Alternatively you can contact Ovarian Cancer Action: Freephone **0300 456 4700,** website www.ovarian.org.uk **and** address: 8-12 Camden High St, London NW1 0JH.

If during the course of the study you have any questions regarding your participation or would like further study specific information before making your decision please contact:

Doctor:

Name Insert *local details*

Telephone Number *Insert local details*

Research Nurse:

Name Insert *local details*

Telephone Number *Insert local details*

24-Hour / out of hours contact: *Insert local details*

If you find the wording difficult to understand or would like us to explain things to you once more, please feel free to ask your doctor or nurse.

Thank you for taking the time to read this information sheet. If you wish to take part you will be given a copy of this information sheet and a signed consent form to keep.

(Form to be on hospital headed paper)

CONSENT FORM FOR PATIENTS/ VOLUNTEERS IN CLINICAL RESEARCH PROJECT

Patient Identification Number for this study:

(to be obtained post registration/randomisation)

Title of Project:

PAIRS: PARP Inhibitor Resistance Study (PAIRS) COHORT A

IRAS ID: 297051

	Please initial box
1. I confirm that I have read and understand the patient information sheet Version 2.0, 23rd November 2023 for the above study, that I fully understand what is involved in taking part in this study, and that I have had the opportunity to ask questions.	☐
2. I understand that my participation is voluntary and that I am free to withdraw at any time, without giving any reason, without my medical care or legal rights being affected.	☐
3. I agree that relevant sections of any of my medical notes and data collected during the study may be looked at by responsible individuals from the Cancer Research UK Clinical Trials Unit (Glasgow), the study Sponsor, the NHS organisation, and personnel from Wellbeing of Women and/or Artios Pharma Limited where it is relevant to my taking part in research. I give permission for these individuals to have access to my records.	☐
4. I understand that the information collected about me will be used to support other research in the future, and may be shared anonymously with other researchers.	☐
5. I agree to the information detailed in the information sheet to be collected as part of the study.	☐

6. I understand that a letter and information regarding my participation in this study will be sent to my GP. ☐

7. I agree to take part in the above study. ☐

8. I give my permission to give extra samples of blood for research purposes and to be kept for future research as described in the information sheet for the above study. I understand how the samples will be collected, that giving samples is voluntary, and that I'm free to withdraw my approval for use of the samples at any time without giving a reason and without my medical care or legal rights being affected. ☐

9. I give my permission for the research team to collect a tumour biopsy sample for research purposes and to be kept for future research as described in the information sheet for the above study. I understand how the samples will be collected, that giving samples is voluntary, and that I'm free to withdraw my approval for use of the samples at any time without giving a reason and without my medical care or legal rights being affected. ☐

10. I give my permission for samples from the stored tumour tissue that was removed during my operation and was not needed for routine diagnosis and treatment to be collected and used for future research purposes as described in the information sheet for the above study. I understand how the tissue sample will be retrieved, that giving permission to use my samples is voluntary, and that I'm free to withdraw my approval for use of the samples at any time without giving a reason and without my medical care or legal rights being affected. ☐

OPTIONAL

	Please initial YES	NO
1. I agree to give permission for data collected relating to me to be used for "Cancer Research" purposes as described in this information sheet including allowing this data to be linked to data coming from other sources such as cancer registries and medical records. I understand giving consent to the use of this data as described is optional and not mandatory for participating in this study.	☐	☐
2. I wish to be informed of any inherited mutations found during this research project and consent to confirmatory testing if appropriate. If you or your family wish to be referred to the Clinical Genetics Service this can be arranged through your doctor.	☐	☐
3. In the event that I am no longer alive, I wish my next-of-kin to be informed of any inherited mutations found during this research project	☐	☐

Please sign and date below:

Name of Patient	Date	Signature

Name of Person taking consent	Date	Signature

When completed, 1 original for researcher; 1 original or photocopy for patient; 1 original or photocopy to be kept with hospital notes